Skip to main content
. 2020 Aug 21;21(17):6037. doi: 10.3390/ijms21176037

Figure 4.

Figure 4

Determination of the binding affinity and ADCC and CDC activities of EMab-17 or EMab-51 using flow cytometry. (A) HCT-15 (Top) and HCT-116 (Bottom) cells were suspended in 100 μL of serially diluted EMab-17 or EMab-51 (6 to 100 ng/mL), followed by the addition of secondary anti-mouse IgG. Fluorescence data were collected using a cell analyzer. (B) The ADCC and CDC activities of EMab-17 or EMab-51 against HCT-15 (Top) or HCT-116 (Bottom) cells were evaluated. ADCC activity was evaluated through the calcein-AM release assay in the presence of antibodies (100 μg/mL; effector/target ratio, 12.5, 25 and 50). CDC activity was determined using the MTS assay in the presence of antibodies (100 μg/mL) or control mouse IgGs (IgG1 or IgG2a, 100 μg/mL) with 10% rabbit complement. The values are means (SD). *: p < 0.05, **: p < 0.01 vs. IgG2a-treated control.